Phytate Effects on Incomplete Distal Renal Tubular Acidosis

Area of Science:

• Nephrology
• Metabolic Bone Disease
• Urology

Background:

• Incomplete distal renal tubular acidosis (dRTA) in adults can lead to recurrent urolithiasis due to metabolic acidosis, bone resorption, hypercalciuria, and urine alkalinization.
• Oral potassium citrate is a common treatment for dRTA, but patient intolerance limits its use.
• Phytate, an inhibitor of bone resorption, is explored as a therapeutic agent for dRTA complications.

Purpose of the Study:

• To evaluate the effect of oral calcium magnesium phytate on calciuria in patients with incomplete dRTA.
• To assess phytate as a potential treatment for hypercalciuria in patients intolerant to potassium citrate.

Main Methods:

• A single-arm study involving 16 adult patients with incomplete dRTA and urolithiasis.
• Calciuria levels were measured at baseline and after 6 months of treatment with oral calcium magnesium phytate (380 mg twice daily).
• No dietary changes or other concomitant treatments were implemented during the study.

Main Results:

• Baseline calciuria averaged 317 ± 81 mg/24 h.
• After 6 months of calcium magnesium phytate treatment, calciuria decreased significantly to 221 ± 38 mg/24 h (p < 0.005).

Conclusions:

• Calcium magnesium phytate demonstrates a significant reduction in calciuria in patients with incomplete dRTA.
• This phytate formulation may serve as an effective alternative or adjunctive therapy for hypercalciuria in this patient population.
• Further consideration of calcium magnesium phytate is warranted for managing dRTA-associated hypercalciuria.